Skip to main content

Advertisement

SpringerLink
Log in

Monoamine Oxidase Inhibitors

A Perspective on their Use in the Elderly

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson’s disease. While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction.

Drug tolerability data for the elderly show that moclobemide is one of the most well tolerated compounds. Selegiline, especially when used in combination with levodopa, can cause anorexia, dry mouth, dyskinesia and, most problematic, orthostatic hypotension. For the traditional MAOIs, phenelzine and tranylcypromine, published data are insufficient to be able to give a conclusive tolerability statement regarding the use of these compounds in elderly people. Although orthostatic hypotension occurs in most patients treated with traditional MAOIs, the incidence in elderly patients with depression does not appear to be greater than that reported with tricyclic antidepressants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenawalt JW. Localization of monoamine oxidase in rat liver. Adv Biochem Psychopharmacol 1972; 5: 207–26

    PubMed  CAS  Google Scholar 

  2. Baker GB, Coutts RT, Young JM, et al. Chronic administration of monoamine oxidase inhibitors: basic and clinical investigations. In: Boulton AA, editor. Neuropharmacology of the trace amines. Clifton: Humana Press, 1985: 317–28

    Chapter  Google Scholar 

  3. Kochersperger LM, Parker EL, Siciliano M, et al. Assignment of genes for human monoaminooxidase A and B to the X chromosome. J Neurosci Res 1986; 16: 602–16

    Article  Google Scholar 

  4. Kettler R, Cesura A, Richards JG, et al. Monoamino-oxidasehemmer: Neurobiochemie, Wirkungsmechanismus. In: Riederer P, Laux G, Pöldinger W, editors. Neuropsycho-pharmaka vol. III. Vienna: Springer, 1993: 293–305

    Google Scholar 

  5. Strolin-Benedetti M, Dostert P. Overview of the present state of MAO inhibitors. J Neural Transm 1987; 23 Suppl.: 103–19

    CAS  Google Scholar 

  6. Cesura A, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992; 38: 171–297

    PubMed  CAS  Google Scholar 

  7. Murphy D, Aulakh CS, Garrick NA, et al. Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 545–52

    Google Scholar 

  8. Laux G, Classen W, Sofic E, et al. Clinical, biochemical, and psychometric findings with the new MAO-A inhibitors moclobemide and brofaromine in patients with major depressive disorder. J Neural Transm 1990; 32 Suppl.: 189–95

    CAS  Google Scholar 

  9. Nakamura S, Kawamata T, Akiguchi I, et al. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 1990; 80: 319–25

    Article  Google Scholar 

  10. Calne DB. The free radical hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992; 32: 804–12

    Article  Google Scholar 

  11. Strolin-Benedetti M, Dostert P. Monoamine oxidase, brain aging and degenerative diseases. Biochem Pharmacol 1989; 38: 555–61

    Article  PubMed  CAS  Google Scholar 

  12. Gleiter CH, Volz HP. MAO-A inhibitors — state of the art. Exp Opin Invest Drugs 1996; 5: 409–419

    Article  CAS  Google Scholar 

  13. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959, 1: 1491–4

    Article  PubMed  CAS  Google Scholar 

  14. Raskin A, Schulterbrandt JG, Raetig N, et al. Depression subtypes and response to phenelzine, diazepam and a placebo. Arch Gen Psychiatry 1974; 30: 66–75

    Article  PubMed  CAS  Google Scholar 

  15. Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 1995; 3: 145–58

    Article  CAS  Google Scholar 

  16. Liebowitz MR, Klein DF. Hysteroid dysphoria. Psychiatr Clin North Am 1979; 2: 555–75

    Google Scholar 

  17. Nies A, Robinson DS. Monoamine oxidase inhibitors. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1982: 246–61

    Google Scholar 

  18. Paykel ES, White JL. A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 1989; 155Suppl. 6: 9–17

    Google Scholar 

  19. Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 1990; 360 Suppl.: 29–34

    Article  CAS  Google Scholar 

  20. Larsen JK. MAOIs in the treatment of depression: a review. Eur J Psychiatry 1991; 5: 79–88

    Google Scholar 

  21. Nolen WA, van de Putte JJ, Dijken WS, et al. Treatment strategies in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants. Acta Psychiatr Scand 1988; 78: 676–83

    Article  PubMed  CAS  Google Scholar 

  22. Volz HP, Gleiter CH, Möller HJ. Monoamine oxidase inhibitors in psychiatric medicine: the status quo. Nervenarzt 1996; 67: 339–47

    PubMed  CAS  Google Scholar 

  23. Tyrer P. Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 1976; 128: 354–60

    Article  PubMed  CAS  Google Scholar 

  24. Sheehan DV, Ballenger J, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51–9

    Article  PubMed  CAS  Google Scholar 

  25. Wiseman LR, McTavish D. Selegiline: a review of its clinical efficacy in parkinson’s disease and its clinical potential in alzheimer’s disease. CNS Drugs 1995; 4: 230–46

    Article  CAS  Google Scholar 

  26. Lees AJ. Selegeline hydrochloride and cognition. Acta Neurol Scand 1991; 84Suppl. 136: 91–4

    Article  Google Scholar 

  27. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm 1989; 28 Suppl.: 21–31

    CAS  Google Scholar 

  28. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561–96

    Article  PubMed  CAS  Google Scholar 

  29. Sunderland T, Cohen RM, Mochan S, et al. High-dose selegeline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607–15

    Article  PubMed  CAS  Google Scholar 

  30. Vestal RE, Montamant SC, Nielson CP. Drugs in special patient groups: the elderly. In: Melmon KL, Morelli HF, Hoffman BB, et al., editors. Melmon and Morellis Clinical Pharmacology. New York: McGraw-Hill, 1992: 851–74

    Google Scholar 

  31. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. 3rd ed. Philadelphia (PA): American College of Physicians, 1994

    Google Scholar 

  32. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Phar-macokinet 1995; 29: 292–332

    Article  CAS  Google Scholar 

  33. Maguire K, Pereira A, Tiller J. Moclobemide pharmacokinetics in depressed patients: lack of age effect. Hum Psycho-pharmacol Clin Exp 1991; 6: 249–52

    Article  Google Scholar 

  34. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995; 19: 39–46

    Article  Google Scholar 

  35. Volz HP, Gleiter CH, Waldmeier PC, et al. Brofaromine — a review of its pharmacological properties and therapeutic use. J Neural Transm 1996; 103: 217–45

    Article  PubMed  CAS  Google Scholar 

  36. Waitzinger J, Ludwig G, Pabst G, et al. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (1-deprenyl). Int J Clin Pharmacol Ther 1996; 34: 427–32

    PubMed  CAS  Google Scholar 

  37. Kerr JS, Fairweather DB, Hindmarch I. The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers. Hum Psychopharmacol Clin Exp 1992; 7: 273–9

    Article  CAS  Google Scholar 

  38. Lavie P, Aharon-Peretz J, Klein F, et al. Sleep quality in geriatric depressed patients: comparison with elderly demented patients and normal controls and the effects of moclobemide. Dementia 1992; 3: 360–6

    Google Scholar 

  39. Ashford JW, Ford CV. Use of MAO inhibitors in elderly patients. Am J Psychiatry 1979; 136: 1466–7

    PubMed  CAS  Google Scholar 

  40. Robinson DS. Monoamine oxidase inhibitors and the elderly. In: Raskin A, Robinson DS, editors. Age and pharmacology of psychoactive drugs. New York: Elsevier, 1981: 151–62

    Google Scholar 

  41. Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depression and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983; 18: 195–205

    PubMed  CAS  Google Scholar 

  42. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996; 36: 95–105

    Article  PubMed  CAS  Google Scholar 

  43. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs vs TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155–66

    Article  PubMed  CAS  Google Scholar 

  44. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46: 783–6

    Article  PubMed  CAS  Google Scholar 

  45. Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989; 28: 1–9

    Article  PubMed  CAS  Google Scholar 

  46. Georgotas A, McCue RE, Friedman E, et al. A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. J Clin Psychopharmacol 1987; 7: 413–6

    Article  PubMed  CAS  Google Scholar 

  47. Georgotas A, McCue RE, Cooper TB, et al. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate. Arch Gen Psychiatry 1988; 45: 429–32

    Article  Google Scholar 

  48. Bugarski-Kirola D, Zivkovic Z, Stankovic Z, et al. Fluoxetine vs moclobemide in elderly depressed patients [abstract]. Eur Neuropsychopharmacol 1996; 6Suppl. 1: 20

    Article  Google Scholar 

  49. De Vanna M, Kummer J, Agnoli A, et al. Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychiatr Scand 1990; 360 Suppl.: 64–6

    Article  Google Scholar 

  50. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. Int J Geriatr Psychiatry 1990; 5: 199–204

    Article  Google Scholar 

  51. Bocksberger JP, Gachoud JP, Richard J, et al. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993; 8: 319–24

    Google Scholar 

  52. Pancheri P, Delle Chiaie R, Donnini M, et al. Effects of moclobemide on depressive symptoms and cognitve performance in a geriatric population: a controlled comparative study vs imipramine. Clin Neuropharmacol 1994; 17Suppl. 1: 58S–73S

    Article  Google Scholar 

  53. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995; 33: 1–9

    Article  PubMed  CAS  Google Scholar 

  54. Roth M, Mountjoy R, Amrein R, et al. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996; 168: 149–57

    Article  PubMed  CAS  Google Scholar 

  55. Allain H, Cougnard J, Neukirch HC, et al. Selegeline in de novo Parkinsonian patients: the French selegeline multicenter trial (FSMT). Acta Neurol Scand 1991; 84Suppl. 136: 73–8

    Article  Google Scholar 

  56. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegeline in de novo parkinsonian patients. Mov Disord 1993; 8Suppl. 1: 36S–40S

    Article  Google Scholar 

  57. Shoulson I. An interim report of the effect of selegeline (L-deprenyl) on the progression of disability in early Parkinson’s disease. Eur Neurol 1992; 32Suppl. 1: 46–53

    Article  PubMed  Google Scholar 

  58. The Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinsons disease. N Engl J Med 1989; 321: 1364–77

    Article  Google Scholar 

  59. Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegeline in de novo Parkinsonian patients: the Finnish study. Mov Disord 1993; 8Suppl. 1: 41S–4S

    Article  Google Scholar 

  60. Chouza C, Aljanati R, Scaramelli A, et al. Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta Neurol Scand 1989; 126: 127–37

    Article  CAS  Google Scholar 

  61. Heinonen EH, Rinne UK, Tuominen J. Selegeline in the treatment of daily fluctuations in disability of Parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand 1989; 126: 113–8

    CAS  Google Scholar 

  62. Sivertsen B, Dupont E, Mikkelsen B, et al. Selegeline and levodopa in early or moderately advanced Parkinson’s disease: a double-blind controlled short- and long-term study. Acta Neurol Scand 1989; 126: 147–52

    Article  CAS  Google Scholar 

  63. Takahashi M, Yuasa R, Imai T, et al. Selegeline (1-deprenyl) and l-dopa treatment of Parkinsons disease: a double-blind trial. Intern Med 1994; 33: 517–24

    Article  PubMed  CAS  Google Scholar 

  64. Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of 1-deprenyl in Alzheimers disease. Psychopharmacology 1987; 91: 489–95

    Article  PubMed  CAS  Google Scholar 

  65. Monteverde A, Gnemmi P, Rossi F, et al. Selegeline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990; 12: 315–22

    PubMed  CAS  Google Scholar 

  66. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of 1-deprenyl in Alzheimers type dementia. Clin Neuropharmacol 1990; 13: 147–63

    Article  PubMed  CAS  Google Scholar 

  67. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991; 31: 100–7

    Article  PubMed  CAS  Google Scholar 

  68. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegeline in patients with early, mild Parkinsons disease. BMJ 1995; 311: 1602–7

    Article  PubMed  CAS  Google Scholar 

  69. Waters CH. Side effects of selegeline (eldepryl). J Geriatr Psychiatry Neurol 1992; 5: 31–4

    PubMed  CAS  Google Scholar 

  70. Noyes MA. Case report of drug-induced serotonin-syndrome in an elderly man [abstract]. Int Pharm Abs 1995; 32: 2355

    Google Scholar 

  71. Garcia-Monco J, Padierna A, Beldarrain MG. Selegeline, fluoxetine, and depression in Parkinson’s disease [abstract]. Mov Disord 1995; 10: 352

    Article  PubMed  CAS  Google Scholar 

  72. Yuh PH, Lai CT, Boulton AA. Effect of adding selegeline to levodopa in early, mild Parkinson’s disease: selegeline may be toxic in presence of increased dopamine concentrations [letter]. BMJ 1996; 312: 703–4

    Google Scholar 

  73. Jellinger KA. Effect of adding selegeline to levodopa in early, mild Parkinson’s disease: causes of death need confirmation [letter]. BMJ 1996; 312: 704–5

    Article  PubMed  CAS  Google Scholar 

  74. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa combined with selegeline in patients with early, mild Parkinson’s disease. BMJ 1995; 311: 1602–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hans-Berger-Kliniken, Klinik für Psychiatrie, Friedrich-Schiller-Universität Jena, Philosphenweg 3, D-07740, Jena, Germany

    Hans-Peter Volz

  2. Abteilung Klinische Pharmakologie, Georg-August-Universität Göttingen, Göttingen, Germany

    Christoph H. Gleiter

Authors
  1. Hans-Peter Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph H. Gleiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Volz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volz, HP., Gleiter, C.H. Monoamine Oxidase Inhibitors. Drugs Aging 13, 341–355 (1998). https://doi.org/10.2165/00002512-199813050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199813050-00002

Keywords

Search

Navigation